Keymed Biosciences Inc (HKSE:02162) Share Price

Company Profile

Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHN
T: +86 2888610620
https://www.keymedbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,258

Recommended

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Malik Ahmed Khan, CFA | 30 July 2025

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.

Angus Hewitt, CFA | 30 July 2025

Our latest articles about where we see opportunities in the market.

Morningstar | 28 July 2025

Index	Last price	Change	% Change
All Ordinaries	9,015.40	48.70	0.54%
CAC 40	7,861.96	4.60	0.06%
DAX 40	24,262.22	44.85	0.19%
Dow JONES (US)	44,643.57	10.58	0.02%
FTSE 100	9,136.94	0.62	0.01%
HKSE	25,176.93	347.52	-1.36%
NASDAQ	21,190.52	92.23	0.44%
Nikkei 225	40,654.70	19.85	-0.05%
NZX 50 Index	12,855.97	80.44	-0.62%
S&P 500	6,383.62	12.76	0.20%
S&P/ASX 200	8,756.40	51.80	0.60%
SSE Composite Index	3,615.72	6.01	0.17%